^
    over3years
    #OncoAlert Report @JTOonline @IASLC on phase II #ATOMIC study of brigatinib in #ALK NSCLC after next-gen ALK TKI therapy. RR 40%, DOR 5.3m, mPFS 7m. Responses seen with ALK resistance mutations (G1202R, I1171T, L1196M). @rdoebele @HornLeora #LCSM https://t.co/aoWJ1Gu0NP (@StephenVLiu)
    ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation • ALK G1202R • ALK I1171T • ALK I1171 • ALK L1196M • ALK L1196M + ALK G1202R
    |
    Alunbrig (brigatinib)
    almost4years
    #ASCO20 Response to brigatinib (post-alectinib) noted in the presence of various #ALK resistance mutations including G1202R (1/3), L1196M (3/3), I1171N (1/2), I1171S (1/1). Well tolerated. Most common G3 tox were lipase (no pancreatitis), CK (no myalgias), HTN. #OncoAlert #LCSM (@StephenVLiu)
    ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation • ALK G1202R • ALK I1171N • ALK I1171 • ALK L1196M • ALK I1171S • ALK L1196M + ALK G1202R
    |
    Alecensa (alectinib) • Alunbrig (brigatinib)